Patent ID: 7858329

Claim:
A method for the diagnosis of or the prognosis of a treatment for a disorder with an HDAC inhibitor comprising (a) contacting a sample obtained from a tissue affected by the disorder with a monoclonal antibody which is (1) monoclonal antibody T25 which is obtainable from the cell line G2M-T25-H4ac deposited at DSMZ (accession no. ACC2578); or (2) monoclonal antibody T52 which is obtainable from the cell line G2M-T52-ac deposited at DSMZ (accession no. ACC2579); wherein each of said T25 or T52 monoclonal antibody is capable of binding to acetylated histone but not to deacetylated histone; and (b) determining the level of histone acetylation in the sample with said T25 or said T52 antibody; wherein lowered level of histone acetylation in said sample compared to that of a reference sample is indicative that said disorder is treatable with said HDAC inhibitor.